A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

* Diagnosis of ulcerative colitis for greater than 90 days prior to Baseline. * Active ulcerative colitis with a Mayo Score of 6-12 points at Baseline and endoscopy subscore of 2-3 during the Screening Period, despite concurrent treatment with at least one of the following (oral corticosteroids or immunosuppressants or both as defined below): * Stable oral corticosteroid dose (prednisolone dose of ≥ 20 mg/day or equivalent) for at least 14 days prior to Baseline or stable oral corticosteroid dose (prednisolone of 5 to less than 20 mg/day) for at least 40 days prior to Baseline. And/or * At least a consecutive 90-day course of azathioprine or 6-mercaptopurine (6-MP) prior to Baseline, with a dose of azathioprine ≥ 50 mg/day or 6-MP ≥ 30 mg/day, or a dose that was the highest tolerated by the patient.

* History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for ulcerative colitis or was planning bowel surgery. * Patients with disease limited to the rectum. * Indeterminate colitis and/or Crohn's disease. * Received any biological therapy (including infliximab) in the past. * History of tuberculosis or malignancy. * Pregnant women. * Patients with positive C. difficile stool assay at Screening. * Current diagnosis of fulminant colitis and/or toxic megacolon.